LakeShore Biopharma Co., Ltd.: 5%+ holders

LakeShore Biopharma Co., Ltd. has 9 Schedule 13D or 13G filings on record since 2025-07-15. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.0002 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Fung Ching Wong

Item 4 of the Original Schedule 13D is hereby amended to add the following information: This Amendment No. 1 is being filed to report a material decrease in the Reporting Persons' percentage of beneficial ownership of the Issuer's Ordinary Shares. This decrease resulted solely from an increase in the total number of the Issuer's issued Ordinary Shares following a private placement transaction announced by the Issuer on July 8, 2025. The Reporting Persons have not sold or otherwise disposed of any of the Ordinary Shares they beneficially own.Item 4 of the SCHEDULE 13D/A filed 2025-07-15

Crystal Peak Investment Inc.

Item 4 is hereby amended and supplemented by adding the following at the end thereof: On June 19, 2026, an extraordinary general meeting of the shareholders of the Issuer was held. At the extraordinary general meeting, the shareholders of the Issuer authorized and approved the Merger Agreement, the plan of merger (the "Plan of Merger") required to be registered with the Registrar of Companies of the Cayman Islands (the "Cayman Registrar") in connection with the Merger, and the consummation of the transactions contemplated thereby, including the Merger. Pursuant to the A&R Support Agreement entered into by and among the Rollover Shareholders, Parent and the Issuer, the Rollover Shareholders have agreed, among other things, to (i) cancel the Rollover Shares beneficially owned by them for no cash consideration and (ii) subscribe for newly issued shares of Parent at or immediately prior to the Effective Time (as defined below). The information disclosed in this paragraph does not purport to be complete and is qualified in its entirety by reference to the A&R Support Agreement, a copy of which is filed as Exhibit 99.22 to the Schedule 13D and is incorporated herein by reference in its entirety. On June 24, 2026, the Issuer and Merger Sub filed the Plan of Merger with the Cayman Registrar, which was registered by the Cayman Registrar as of June 24, 2026, pursuant to which the Merger became effective on June 24, 2026 (the "Effective Time"). As a result of the Merger, the Issuer …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-25; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes